Biogen Outlook For The 2020s

12/3/18

By William Meyers, SeekingAlpha

Summary

Current therapies are driving revenue growth of 12% y/y.

RNA-based therapy collaboration with Ionis should generate more Spinraza-like wins.

Neurological disease pipeline is broad and will likely drive revenue growth throughout the 2020s.

These days, if you hold a stock for more than twenty-four hours, you might claim to be a long-term investor. The market is driven, microsecond to microsecond, by trading algorithms. But, in the longer long run, measured in years or decades, companies need to make profits to justify their stock prices. Today, I will focus on one biotech pharmaceutical company that is likely to richly reward investors between now and 2029: Biogen (BIIB).

While I will focus on the future, because that is where the investment value is, Biogen has a past. It was formed in 1978 and began public trading in 1983. When I first bought some of its stock, in 2007, it had annual revenue of $3.2 billion. In 2017, annual revenue was $12.3 billion.

On the other hand, like most of the stock market, and biotechs, in particular, it has experienced more than normal volatility in the last year, as can be seen from this chart:

READ FULL ARTICLE HERE